Lynparza Maintenance Delays Disease Progression in Advanced Ovarian Cancer, Phase 3 Trial Shows

Lynparza Maintenance Delays Disease Progression in Advanced Ovarian Cancer, Phase 3 Trial Shows
Lynparza (olaparib), a PARP inhibitor, significantly prevents ovarian cancer from progressing or returning in women who responded to their first-line chemotherapy treatment, results from a Phase 3 trial show. The randomized, double-blind, placebo-controlled study, called SOLO-1 (NCT01844986), assessed Lynparza as a maintenance therapy for patients with advanced ovarian cancer, who had a BRCA mutation in their tumor, and were at a high risk of progressing. Patients were still responding — partially or completely — to first-line platinum-based chemotherapy. Lynparza is the first PARP inhibitor showing benefits as a first-line maintenance treatment. Now that the trial has met its primary goal, AstraZeneca and Merck — which are jointly developing and commercializing Lynparza — are planning to submit the data to health authorities. “For the first time, we see a significant and clinically-impactful improvement in progression-free survival in the 1st-line maintenance setting for women with BRCA-mutated ovarian cancer treated with a PARP inhibitor," Sean Bohen, executive vice president of global medicines development and chief medical officer at AstraZeneca, said in a press release. "The SOLO-1 data reinforce the importance of knowing BRCA status at diagnosis, as this may enable
Subscribe or to access all post and page content.